- $485.75m
- $508.98m
- $185.36m
- 92
- 58
- 86
- 93
Annual income statement for biote, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 110 | 117 | 139 | 165 | 185 |
Cost of Revenue | |||||
Gross Profit | 66.4 | 71.6 | 90.6 | 110 | 127 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 86.4 | 84.8 | 105 | 226 | 157 |
Operating Profit | 23.5 | 31.8 | 34.6 | -61.2 | 28.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 21.4 | 29.4 | 32.9 | 1.71 | -0.123 |
Provision for Income Taxes | |||||
Net Income After Taxes | 21.3 | 29.2 | 32.6 | 1.32 | -2.81 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 21.3 | 29.2 | 32.6 | -0.969 | 3.32 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 21.3 | 29.2 | 32.6 | -0.969 | 3.32 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 2.55 | 3.5 | 3.41 | -2.22 | 0.488 |
Dividends per Share |